Skip to main content
Royalty Pharma plc (FRA:RPD)
Germany flag Germany · Delayed Price · Currency is EUR
29.65
+0.23 (0.78%)
Last updated: May 13, 2025

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Total Income from Financial Royalty Assets
2.15B
Log In
Log In
Log In
Log In
Total Income from Financial Royalty Assets Growth
-2.20%
Log In
Log In
Log In
Log In
Revenue from Intangible Royalty Assets
-
Log In
Log In
Log In
Log In
Revenue from Intangible Royalty Assets Growth
-
Log In
Log In
Log In
Log In
Other Royalty Income
-
Log In
Log In
Log In
Log In
Other Royalty Income Growth
-
Log In
Log In
Log In
Log In
Other Royalty Income and
114.15M
Log In
Log In
Log In
Log In
Other Royalty Income and Growth
-27.20%
Log In
Log In
Log In
Log In
Cystic Fibrosis Franchise
826.21M
Log In
Log In
Log In
Log In
Cystic Fibrosis Franchise Growth
-3.06%
Log In
Log In
Log In
Log In
Imbruvica
131.09M
Log In
Log In
Log In
Log In
Imbruvica Growth
-24.30%
Log In
Log In
Log In
Log In
Tysabri
124.82M
Log In
Log In
Log In
Log In
Tysabri Growth
-25.50%
Log In
Log In
Log In
Log In
Xtandi
-
Log In
Log In
Log In
Log In
Xtandi Growth
-
Log In
Log In
Log In
Log In
Promacta
-
Log In
Log In
Log In
Log In
Promacta Growth
-
Log In
Log In
Log In
Log In
Tazverik
-
Log In
Log In
Log In
Log In
Other Products
548.82M
Log In
Log In
Log In
Log In
Other Products Growth
-17.96%
Log In
Log In
Log In
Log In
Tremfya
147.14M
Log In
Log In
Log In
Log In
Tremfya Growth
-1.72%
Log In
Log In
Log In
Log In
Trelegy
146.92M
Log In
Log In
Log In
Log In
Trelegy Growth
14.74%
Log In
Log In
Log In
Log In
Evrysdi
224.43M
Log In
Log In
Log In
Log In
Evrysdi Growth
129.61%
Log In
Log In
Log In
Log In

Other

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Portfolio Receipts
2.80B
Log In
Log In
Log In
Log In
Portfolio Receipts Growth
0.81%
Log In
Log In
Log In
Log In